Study of stapokibart for primary cutaneous amyloidosis
Treatments studied
Part of Skin clinical trials.
This study tests whether stapokibart (an investigational biologic) can reduce skin symptoms of primary cutaneous amyloidosis, a condition that causes itchy, discolored patches on the skin. It aims to see if the drug is safe and effective for people whose current treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a skin biopsy confirming primary cutaneous amyloidosis.
- You have had at least moderate itch (score 3 or higher on a 0–4 scale) and moderate to severe skin involvement.
- You've tried at least 4 weeks of medium-to-high potency steroid creams or 2 weeks of very strong steroid creams or oral steroids, but they didn't work well enough.
- You've been using a moisturizer every day for at least a week before the study starts and must keep using it throughout.
- You must be willing to use reliable birth control during the study and for 6 months after, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
This study tests a new medicine called Stapokibart for children aged 2 to 11 with moderate-to-severe atopic dermatitis (also called eczema) that hasn't improved with topical creams. The medicine is given as an injection and may help reduce itching and skin symptoms.
This trial tests a new injection called Stapokibart to see if it can help people with moderate to severe bullous pemphigoid, a skin condition that causes painful blisters. The treatment aims to reduce blistering and itching.
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This trial tests a new drug called tulisokibart for people with psoriatic arthritis (PsA), a condition that causes joint pain and skin plaques. It may help if you have not tried certain biologic medications or if they did not work well.
Hear when a new Primary Cutaneous Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.